TGen identifies compound that could improve drug development against deadly brain cancer
A study led by scientists at the TGen has identified “a potent inhibitory compound” in the elusive hunt for an improved treatment against glioblastoma, the most common and deadly type of adult brain cancer. The TGen-led report was published in the scientific journal Oncotarget. January 17, 2017